The Dysregulated IL-23/TH17 Axis in Endometriosis Pathophysiology
The Journal of Immunology · 01.05.2024 · 212 (9) · 1428-1441
DOI: 10.4049/jimmunol.2400018 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 11.03.2024. Verfasst von Danielle J Sisnett und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. Hauptthemen laut MEDLINE: Endometriosis, Interleukin-23, Th17 Cells. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
Endometriosis is a chronic inflammatory disease in which endometrial-like tissue grows ectopically, resulting in pelvic pain and infertility. IL-23 is a key contributor in the development and differentiation of TH17 cells, driving TH17 cells toward a pathogenic profile. In a variety of inflammatory and autoimmune disorders, TH17 cells secrete proinflammatory cytokines, including IL-17, contributing to disease pathophysiology. Our studies and others have implicated IL-17 and TH17 cell dysregulation in endometriosis, which is associated with disease severity. In this article, we address whether IL-23–driven TH17 cells contribute to cardinal features of lesion proliferation, vascularization, and inflammation in endometriosis using patient samples, representative cell lines, and our established mouse model of endometriosis. The results indicated dysregulated expression of key genes in the IL-23/TH17 axis in patient ectopic and eutopic endometrial samples and increased IL-23 protein in patient plasma compared with controls. In vitro studies using primary human TH cells determined that rIL-23 mixture treatment increased pathogenic TH17 cell frequency. Similarly, rIL-23 treatment of cell lines (12Z cells, EECCs, HUVECs, and hESCs) representative of the endometriotic lesion microenvironment increased cytokines and growth factors, which play a role in lesion establishment and maintenance. In a syngeneic mouse model of endometriosis, rIL-23 treatment altered numbers of myeloid and T cell subsets in peritoneal fluid and increased giant cells within the lesion. Lesions from rIL-23–treated mice did not reveal significant alterations in proliferation/vascularization, although trends of increased proliferation and vascularization were observed. Collectively, these findings provide insights into the impact of the IL-23/TH17 axis on local immune dysfunction and broadly on endometriosis pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
- Department of Obstetrics and Gynaecology, Kingston Health Sciences Centre, Kingston, ON, Canada.
- School of Medicine, Wake Forest University, Winston-Salem, NC.
ORCID-Profile: Danielle J Sisnett, Katherine B Zutautas, Soo Hyun Ahn, Alison McCallion, Chandrakant Tayade
Förderung
- Canadian Government | Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Sisnett, D. J., Zutautas, K. B., Miller, J. E., Lingegowda, H., Ahn, S. H., McCallion, A., Bougie, O., Lessey, B. A., & Tayade, C. (2024). The Dysregulated IL-23/TH17 Axis in Endometriosis Pathophysiology. The Journal of Immunology, 212(9), 1428-1441. https://doi.org/10.4049/jimmunol.2400018
Vancouver
Sisnett DJ, Zutautas KB, Miller JE, Lingegowda H, Ahn SH, McCallion A, et al. The Dysregulated IL-23/TH17 Axis in Endometriosis Pathophysiology. The Journal of Immunology. 2024;212(9):1428-1441. doi:10.4049/jimmunol.2400018
BibTeX
@article{Sisnett2024,
author = {Sisnett, Danielle J and Zutautas, Katherine B and Miller, Jessica E and Lingegowda, Harshavardhan and Ahn, Soo Hyun and McCallion, Alison and Bougie, Olga and Lessey, Bruce A and Tayade, Chandrakant},
title = {The Dysregulated IL-23/TH17 Axis in Endometriosis Pathophysiology},
journal = {The Journal of Immunology},
year = {2024},
volume = {212},
number = {9},
pages = {1428--1441},
doi = {10.4049/jimmunol.2400018}
}
EUVIMED